asunaprevir

Known as: ASV 
An orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV). Upon administration… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
An estimated 170 million persons worldwide have hepatitis C virus (HCV) infection (1), including 2.7 million to 3.9 million in… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
UNLABELLED All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS The combination of peginterferon and ribavirin with telaprevir or boceprevir is the standard treatment of… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND & AIMS Daclatasvir and asunaprevir are NS5A and NS3 protease-targeted antivirals currently under development for… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND & AIMS Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Review
1999
Review
1999
Thousands of people in different parts of the world are exposed to arsenic via drinking water or contaminated soil or food. The… (More)
Is this relevant?